InvestorsHub Logo
Followers 42
Posts 2198
Boards Moderated 0
Alias Born 02/10/2014

Re: Nadar627KSalary post# 96390

Tuesday, 07/21/2020 8:51:24 AM

Tuesday, July 21, 2020 8:51:24 AM

Post# of 233177
If Cytodyn has nothing of substance to offer, AF wouldn’t cover it.

Nader has always, always said that he provides whatever relevant data there is when he has it. Every shareholder and biotech writer should have that basic understanding of how Nader operates under their belt by now. Further touting the opposite shows the disingenuous of biotech writers and commentators... especially when the report explicitly says,

“39% of Patients in Placebo Arm Had SAEs as Compared to Only 14% of Patients in Leronlimab Arm Had SAEs, Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will be Announced Along With a Full Report as Soon as Statistical Analyses are Completed“

How hard is it for some people understand basic English?

All my posts, comments, and investments are not to be considered investment advice in any way.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News